Relationship between vitamin D status and the inflammatory state in patients with chronic spontaneous urticaria

Alicja Grzanka†, Edyta Machura2, Bogdan Mazur3, Maciej Misiolek4, Jerzy Jochem5, Jacek Kasperski6 and Alicja Kasperska-Zajac1*

Abstract

Background: Chronic spontaneous urticaria (CSU) is an immune-inflammatory disease, characterized by acute phase response (APR) and immune activation. There has been increasing evidence showing that vitamin D deficiency/insufficiency is associated with increased incidence and/or severity of immune-inflammatory disorders.

Aim: To assess relationship between vitamin D status and C-reactive protein (CRP), a nonspecific inflammatory marker of CSU activity.

Methods: Concentrations of CRP and 25-hydroxyvitamin D [25(OH)D], a biomarker of vitamin D status were measured in serum of CSU patients and compared with the healthy controls.

Results: Serum 25(OH)D concentration was significantly lower in CSU group as compared with the normal subjects. The prevalence of vitamin D deficiency (< 20 ng/ml) was significantly higher in patients with CSU than among normal population. There were no significant differences in prevalence of 25(OH)D insufficiency between the groups. Serum CRP concentrations were significantly higher in CSU patients as compared with the healthy subjects. There were no significant correlations between CRP and 25(OH)D concentrations in CSU patients.

Conclusions: CSU is associated with lower serum 25(OH)D concentration and higher prevalence of its deficiency. The results failed to show any effect of vitamin D status on circulating CRP concentrations in CSU. A potential role of vitamin D in pathogenesis and/or additive therapy of CSU needs to be examined in other cohorts of CSU patients as well as in larger studies.

Keywords: Vitamin D, 25-hydroxyvitamin D, Chronic spontaneous urticaria (CSU), Acute phase response, C-reactive protein

Introduction

Chronic spontaneous urticaria (CSU) is an inflammatory disease, characterized by acute phase response (APR) and in many cases by the immune-activation. C-reactive protein (CRP) is a marker of systemic CSU activity, reflecting the systemic effects of inflammatory mediators associated with the disease, including IL-6 [1-5]. The altered function of the neuro-endocrine-immune system has also been recognized in the pathogenesis [6].

There has been increasing evidence showing that vitamin D deficiency/insufficiency is associated with increased incidence and severity/activity of the immune-inflammatory disorders. Vitamin D has immunomodulatory properties and is able to suppress the inflammatory milieu, including IL-6 and CRP synthesis [7-9]. In the clinical practice, vitamin D status is assessed by measurement of the circulating level of 25-hydroxyvitamin D [25(OH)D], considered as the best indicator of vitamin D status, including its availability [10,11].

Little data are available on vitamin D status in CSU patients. To estimate the prevalence of vitamin D deficiency and insufficiency in CU, serum 25(OH)D concentrations were compared between CSU patients and the healthy

* Correspondence: kasperska@plusnet.pl
†Equal contributors
1Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, M. Curie-Skłodowskiej 10, 41-800 Zabrze, Poland
Full list of author information is available at the end of the article

© 2014 Grzanka et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
controls. In addition, relationship between vitamin D status and C-reactive protein (CRP), a nonspecific inflammatory marker of the disease activity, was assessed.

**Materials and methods**

35 patients with active CSU (20 and 15 men/women; median age: 35 years, range: 22-51) with a median disease duration of 3.5 years were enrolled in the study.

In all cases, any known causes of CSU were ruled out by appropriate investigations. Each patient underwent the following tests: routine laboratory tests (full blood count, urine analysis, ESR, C-reactive protein, serum glucose, hepatic functions, and creatinine), stool (for parasites), hepatitis serology, antinuclear and antithyroid microsomal antibodies, thyroid function tests, chest X-ray and abdominal ultrasonography. Additionally, dental, and ENT consultations as well as the autologous serum skin test (ASST) were performed.

All the patients were divided into several subgroups, according to the urticarial activity score (UAS), autologous serum skin test (ASST), glucocorticoids therapy response as well as serum 25(OH)D concentration defined as: a) sufficiency (≥30 ng/ml), b) insufficiency (between 20 and 29 ng/ml), c) deficiency (< 20 ng/ml), d) critically low level (< 10 ng/ml),

UAS according to EAACI/GALEN/EDF guidelines [12] was estimated during four days and on the blood sampling day and graded as follows: mild (0–8), moderate (9–16) and severe (17–24). The study comprised 12 patients with mild and 23 patients with moderate-severe urticaria symptoms.

H1-antihistamine drugs were withdrawn at least 4 days before blood sampling. At the time of blood sampling, only 9 patients were receiving low doses of oral glucocorticoids (GC) (5–10 mg prednisolone per day). None of the remaining patients had been taking immunosuppressants or any other drugs, for at least 8 weeks before the study.

The control group comprised 33 sex-, age- and BMI (< 30) matched the healthy subjects.

The Ethics Committee of the Medical University of Silesia approved of the study and written informed consent was obtained from all the subjects participating.

**Blood collection**

All blood samples were obtained between 7 and 9 a.m. by antecubital puncture. As the circulating levels of 25(OH)D vary depending on the season, the concentration was evaluated in summer (June through September).

**Assay of 25(OH)D**

Serum 25(OH)D concentration was measured with the use of an automated direct electrochemiluminescence immunoassay (Elecsys, Roche Diagnostic, Mannheim, Germany) with the detection limit of 3.0 ng/ml. Sufficient vitamin D concentration was defined as ≥30 ng/ml.

**Assay of CRP**

Serum CRP concentration was measured by the turbidimetric latex agglutination method (CRP-Latex, Biosystems SA, Barcelona, Spain) with a detection limit of 1.0 mg/l. Elevated serum CRP was defined as higher than 5.0 mg/l.

**Autologous serum skin test (ASST)**

Intradermal ASST was performed following the method by Sabroe et al. [13]. Serum-induced a red wheal response of diameter greater by at least 1.5 mm than that of a control wheal induced by physiological saline was accepted as positive. Skin prick test with histamine served as a positive control.

**Statistical analysis**

Results are expressed as median and inter-quartile ranges. Because data were not distributed normally, non-parametric tests were used. Kruskal-Wallis variance analysis was used to screen differences between the groups. Mann-Whitney U and the Fisher exact tests were used to compare data between the patient groups and the normal population. Spearman’s rank test was used for correlations. The probability value of P < .05 was assumed significant.

**Results**

**Serum 25(OH)D concentration**

Serum 25(OH)D concentration was significantly lower in CSU group as compared with the normal subjects (median: 26.0 vs. 31.1 ng/ml, p = 0.017) (Figure 1). There were no significant differences in serum 25(OH)D concentration between the CSU patients with mild and moderate-severe symptoms (median: 27.3 vs. 22.6 ng/ml,
However, 25(OH)D concentrations were slightly yet significantly lower in moderate-severe CSU than those of the controls (22.6 vs. 31.1 ng/ml, p = 0.048). There were no significant differences in concentrations between mild CSU patients and the healthy subjects (27.3 vs. 31.1 ng/ml, p = 0.13) (Figure 1).

Moreover, there were no significant differences in serum concentrations of 25(OH)D in moderate-severe CSU patients with and without glucocorticoid therapy (p = 0.57).

CSU subgroup without glucocorticoids was significantly lower as compared with the healthy subjects (data not shown).

**Deficiency and insufficiency of vitamin D**

The prevalence of vitamin D deficiency (< 20 ng/ml) was significantly higher in patients with CU than in the normal population. There were no significant differences in the prevalence of 25(OH)D insufficiency (≥20 ng/ml but <30 ng/ml) between CU patients and the normal subjects (Table 1).

**Serum CRP concentration**

Serum CRP concentrations were significantly higher in CSU patients (currently untreated with GC) as compared with the healthy subjects (median: 7.1 vs. 0.8 mg/l, p < 0.0001). There was significant difference in CRP serum concentration between patients with mild and moderate-severe CSU (without GC) (median: 1.7 vs. 11.7 g/L, p < 0.0001). CRP serum concentration was significantly lower in moderate-severe CSU patients with GC as compared with those without GC therapy, and was similar to the healthy subjects (median: 1.8 vs. 11.7 vs. 0.8 g/L, p < 0.5).

No significant differences in 25(OH)D and CRP concentrations between ASST(+) and ASST(-) CU patients were observed.

**Associations**

There were no significant correlations between serum concentrations of CRP and 25(OH)D (r = -0.16, p = 0.45) in CSU patients without GC therapy. In addition, no correlation was found between the disease duration and 25(OH)D concentration.

**Discussion**

To the best of our knowledge, there have only been two reports regarding vitamin D in CU [14,15]. Thorp et al. reported that serum 25(OH)D concentration was reduced as compared to that in patients with allergic rhinitis [14]. However, it has been suggested that the prevalence of severe vitamin D deficiency was significantly higher in patients with allergic rhinitis than among the normal population [16]. Therefore, in the present study we compared CSU patients with the healthy subjects. Similarly to the previous study, serum 25(OH)D concentration in CSU patients decreased as compared with the healthy subjects.

Thorp et al. showed that the proportion of all subjects with vitamin D deficiency (defined as 25-OHD < 30 ng/ml) was not significantly different between the 2 groups: chronic urticaria, 48% (12/25) versus controls, 28% (7/25; p = 0.24) [14]. In our study the subjects were divided into three groups according to serum 25(OH)D concentration, to describe vitamin D status: deficiency (<20 ng/ml), insufficiency (between 21 and 29 ng/ml), critically low level (< 10 ng/ml) as defined by most experts [10,17]. In contrasts to the previous study the proportion of vitamin D deficiency proved significantly higher in CSU patients.

The reason for such discrepancy is unclear, although it may be related to various factors, including 1) differences in the control group (healthy versus allergic rhinitis subjects), 2) seasons during which blood was collected, 3) regions and/or countries, 4) lifestyle. It has been reported that serum 25(OH)D concentrations in the European countries are lower than in the United States [10,17,18].

There were not significant differences in serum 25(OH) D concentrations in CSU patients with and without glucocorticoid therapy. We found no association between serum concentrations of 25-(OH)D and the glucocorticoids doses in CSU patients. This is in accordance with the previous studies indicating that serum 25(OH)D concentration is unaffected by treatment, even with high doses.

**Table 1 Vitamin D status in CSU patients as compared with healthy subjects**

| Serum 25(OH)D concentration | CSU patients | Healthy subjects | p-value |
|-----------------------------|--------------|------------------|---------|
| n = 35                      |              |                  |         |
| Insufficiency               |              |                  |         |
| (≥20 ng/ml but <30 ng/ml)   | 11/35        | 13/33            | p = 0.41|
| Deficiency                  |              |                  |         |
| (<20 ng/ml)                 | 11/35        | 2/33             | p=0.025*|
| Severe deficiency           |              |                  |         |
| (<10 ng/ml)                 | 1/35         | 0/33             | p = 0.52|

25(OH)D - 25-hydroxyvitamin D; CSU - chronic spontaneous urticaria; *statistically significant difference (p<0.05).
doses of glucocorticoids [19]. Taken together, it seems unlikely that the glucocorticoid treatment of our patients is responsible for lower serum concentrations of 25(OH)D.

Although our and Thorp et al. results point to some changes in vitamin D status, such as a decrease in serum 25(OH)D concentration [14], conclusions regarding the reasons for reduced concentration as well as relevance of such results for a possible risk factor in CSU and/or the disease activity cannot yet be drawn. While some data suggest that 25(OH)D levels are associated with an increased activity/severity of the inflammatory diseases [7], we found no relationship between serum concentrations of 25(OH)D and CRP - a marker of CSU activity [20].

Lower 25(OH)D concentration may therefore appear as a mere secondary phenomenon, manifested as a response to different stimuli, including inflammation, and as such, may not contribute in any way to pathogenesis of the disease. As chronic urticaria may be associated with lower serum 25OHD concentration during the active period of the disease, it would be interesting to recognize whether such phenomenon is present shortly after the disease onset and after a long lasting remission, suggesting vitamin D deficiency as a possible risk factor for CSU.

Interestingly, it has been reported that vitamin D metabolites regulate the synthesis of matrix metalloproteinases (MMP) [21] and vitamin D insufficiency is associated with the increased circulating levels of MMP9 and CRP [22], suggesting a possible mechanism for tissue damage in chronic inflammatory conditions, including CHD and diabetes [22]. On the other hand, it is known that both MMP9 and CRP concentrations are elevated in CSU [23]. In our study we did not observe any significant association between concentrations of 25(OH)D and CRP. Associations between vitamin D status and MMP9 overproduction in CSU should be established.

The limitations of this study included small sample size and single assessment of 25(OH)D concentration performed in summer. Because serum 25(OH)D concentrations are lower in winter, it should be interesting to compare the seasonal differences. Therefore, we cannot exclude that prevalence of 25(OH)D deficiency might be higher following the summer season.

The serum 25(OH)D concentrations vary extensively between studies and depend on different environmental factors. Serum 25(OH)D concentration ≥ 30 ng/ml is defined by most experts as optimal vitamin D status with respect to maintenance of mineral homeostasis. So far, immune-inflammatory consequences of vitamin D insufficiency/deficiency, assessed on the basis of 25(OH)D concentrations alone, are unclear [17,18,24].

Conclusions
CSU is associated with lower serum 25(OH)D concentration and higher prevalence of its deficiency. The results failed to show any effect of vitamin D status on the circulating CRP concentrations in CSU. Taking into consideration that increased vitamin D intakes might reduce the incidence and/or severity of immune-inflammatory disorders, the potential role of vitamin D in etiopathogenesis and/or treatment of CSU calls for examination in other cohorts of CSU patients as well as in larger studies.

Abbreviations
CSU: Chronic spontaneous urticaria; APR: Acute phase response; CRP: C-reactive protein; 25(OH)D: 25-hydroxyvitamin D; ASST: Autologous serum skin test; UAS: Urticaria activity score; GC: Glucocorticoids; MMP: Matrix metalloproteinases; ENT: Ear, nose, throat.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AG: conceived and designed the study, collected samples and provided clinical data, contributed to data analysis and interpretation and wrote the manuscript. EM: collected samples and provided clinical data, wrote the manuscript BM: performed the lab analysis, contributed to data analysis and interpretation. MM: provided clinical data (ENT consultations), identified patients and reviewed the manuscript. AKZ: conceived, designed and supervised the study as well as reviewed the manuscript. JJ: contributed to statistical data analysis and reviewed the manuscript. All authors read and approved the final manuscript. JK: provided clinical data (dental consultations) and identified patients.
Acknowledgements
This study was supported by the internal grants from the Medical University of Silesia, Katowice Poland research grant from the Committee for Scientific Research (KNW-11-124/P/2/0, KNW-11-109/P/2/0, KNW-11-081/P/2/0).

Author details
1Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, M. Curie-Skłodowskiej 10, 41-800 Zabrze, Poland. 2Department of Pediatric in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland. 3Department of Microbiology and Immunology in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland. 4Clinical Department of Otolaryngology in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland. 5Department of Basic Medical Sciences in Bytom, Medical University of Silesia in Katowice, Katowice, Poland. 6Department of Prosthetic Dentistry in Bytom, Medical University of Silesia in Katowice, Katowice, Poland.

Received: 2 May 2013 Accepted: 30 January 2014 Published: 3 February 2014

References
1. Kasperska-Zajac A: Acute-phase response in chronic urticaria. J Eur Acad Dermatol Venereol 2012, 26:665–672.
2. Kasperska-Zajac A, Grzanka A, Czeckor E, Misiolk M, Rogala B, Machura E: Acute phase inflammatory markers in patients with non-steroidal anti-inflammatory drugs (NSAIDs)-induced acute urticaria/angioedema and after aspirin challenge. J Eur Acad Dermatol Venereol 2013, 27:1048–1052.
3. Kasperska-Zajac A, Grzanka A, Machura E, Mazar B, Misiolk M, Czeckor E, Kasperski J, Jochem J: Analysis of procalcitonin and CRP concentrations in serum of patients with chronic spontaneous urticaria. Inflamm Res 2013, 62:309–312.
4. Magen E, Mishal J, Zeldin Y, Feldman V, Kidon M, Schlesinger M, Sthoeger Z: Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum test skin. J Am Acad Dermatol 2013, 69:79–87.
5. Kasperska-Zajac A, Grzanka A, Machura E, Mazar B, Jochem J: Increased serum complement C3 and C4 concentrations and their severity of chronic spontaneous urticaria and CRP concentration. J Inflamm 2013, 22:4.
6. Kasperska-Zajac A, Brioza Z, Rogala B: Sex hormones and urticaria. J Dermatol Sci 2008, 52:79–86.
7. Patel S, Faragher T, Berry J, Bunn D, Silman A, Symmons D: Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007, 56:2143–2149.
8. Peterson CA, Heffeman ME: Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm 2008, 24:5–10.
9. Van den Bergh G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R: Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 2003, 88:4623–4632.
10. Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357:266–281.
11. Hollis BW: Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Curr Opin Endocrinol Diabetes Obes 2008, 15:489–494.
12. Altrichter S, Boodstein N, Maurer M: Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy 2009, 64:652–656.
13. Sabroe RA, Grattan CDH, Francis DM, Barr RM, Kolza Black A, Gneaves MW: The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999, 140:446–453.
14. Thorp WA, Goldner W, Meza J, Poole JA: Reduced vitamin D levels in adult subjects with chronic urticaria. J Allergy Clin Immunol 2010, 126:413.
15. Goetz DW: Idiopathic itch, rash, and urticaria/angioedema merit serum vitamin D evaluation: a descriptive case series. W V Med J 2011, 107:14–21.
16. Arshi S, Ghalehi-Baghi B, Kamrava SK, Aminlou M: Vitamin D serum levels in allergic rhinitis: any difference from normal population? Asian Pac J Allergy Immunol 2012, 2:45–48.
17. Kennel KA, Drake MT, Hurley DL: Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 2010, 85:752–757.
18. Thacher TD, Clarke BL: Vitamin D insufficiency. Mayo Clin Proc 2011, 86:50–60.
19. Müller K, Kriegbaum NJ, Baslund B, Sørensen OH, Thymann M, Bentzen K: Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 1995, 14:397–400.
20. Kasperska-Zajac A, Sztylic J, Machura E, Jop G: Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy 2011, 41:1386–1391.
21. Dean DD, Schwartz Z, Schmitz J, Muniz OE, Lu Y, Calderon F, Howell DS, Boyan BD: Vitamin D regulation of metalloproteinase activity in matrix vesicles. Connect Tissue Res 1996, 35:331–336.
22. Timms PM, Marrian N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price C, Coucher BJ: Circulating MMP8, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002, 95:787–796.
23. Tedeschi A, Asero R, Lorrini M, Marzano AV, Cugno M: Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010, 40:875–881.
24. Schwalfenberg GK: A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Mol Nutr Food Res 2011, 55:96–108.
25. Goetz DW: Vitamin D, treatment of idiopathic itch, rash, and urticaria/angioedema. Allergy Asthma Proc 2010, 31:158–160.
26. Searing DA, Zhang Y, Murphy JR, Hauk PJ, Goleva E, Leung DY: Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 2010, 125:995–1000.
27. Dobbing H, Plz S, Schamagl H, Renner W, Sehhorst U, Wehnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W: Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008, 168:1340–1349.

Cite this article as: Grzanka et al.: Relationship between vitamin D status and the inflammatory state in patients with chronic spontaneous urticaria. Journal of Inflammation 2014 11:2.

Submit next manuscript to BioMed Central and take full advantage of:
- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit